{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.70","upperLimit":"27.8","value":"9.87"},{"groupId":"OG001","lowerLimit":"8.55","upperLimit":"8.55","value":"8.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"CR/CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.6","upperLimit":"62.7","value":"20.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"NR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.73","upperLimit":"19.9","value":"13.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.70","upperLimit":"62.7","value":"9.98"},{"groupId":"OG001","lowerLimit":"8.55","upperLimit":"8.55","value":"8.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"All Participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Tmax is the time to reach maximum (peak) peripheral blood drug concentration after single dose administration (days)\", reported by CR/CRi, no response (NR), Unknown and by All participants. D28 refers to the timepoint for definition of responder populations, whereas M60 is the actual timepoint for endpoint assessment. The time frame of 60 months refers to the duration for which the data were reviewed to identify the time of Cmax for this measure.","dispersionType":"Full Range","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"MEDIAN","populationDescription":"PAS: The PAS consisted of patients in the FAS who had at least one sample providing evaluable cellular kinetic data for tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Pharmacokinetics (PK) Parameter: Tmax by qPCR in Peripheral Blood, by Day 28 Disease Response by IRC","type":"SECONDARY","unitOfMeasure":"days"}